Trial shows HbA1c reduced, hypoglycemia and DKA similar across study participants.
Read More »Heart Failure Warning Added to the DPP-4 Inhibitor Class of Drugs
Increased cardio risk of Saxagliptin found during trial prompts FDA decision.
Read More »Two New Treatments Offer Type 1 Patients Greater Weight Loss and A1c Reduction
Trial results promising, but DKA still a concern with use of new once-daily pills.
Read More »Efficacy and Safety of Diacerein With Inadequately Controlled Type 2 Diabetes
Common osteoarthritis treatment may be beneficial in lowering HbA1c.
Read More »Intensive Control Again Shows Greater Benefits
Intensive control of blood pressure, glucose, and lipids benefits patients with type 2 diabetes, the long-awaited, large Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3).
Read More »Abbott’s CGM Libre Approved by FDA
First Continuous Glucose Monitor that doesn’t require routine finger pricks.
Read More »Benefits of CGM’s for Type 1 Patients
Real-time monitoring produces significant long-term improvement in HbA1c.
Read More »EASD: TOSCA IT Study: Older Diabetes Drugs Compared
With fewer side effects, much less expensive drugs still found to be effective.
Read More »Atherosclerotic Cardiovascular Disease Risk (ASCVD) in Diabetes Patients
Treatment of hypoglycemia contributes to ASCVD risk reduction.
Read More »Blood Glucose Test Strips: To Reimburse or Not to Reimburse?
T1D patients with certain characteristics would benefit the most from reimbursement of blood glucose test strips.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.